The engraftment syndrome (ES) is a phenomenon observed in some patients undergoing autologous hematopoietic stem cell transplant (AHSCT). ES is characterized by fever, rash, capillary leak, and pulmonary infiltrates occurring at the onset of engraftment. Prior studies have suggested that the administration of hematopoietic growth factors post-transplant results in the increased frequency of ES. However, the relative contribution of granulocyte colony-stimulating factor (G-CSF) vs granulocyte-macrophage colony-stimulating factor (GM-CSF) to the development of ES remains unknown. A total of 152 consecutive patients who were treated with high-dose chemotherapy and AHSCT supported by either G-CSF or GM-CSF were analyzed retrospectively. In all, 20 patients developed ES, an incidence of 13%. ES was seen more frequently in patients who received GM-CSF (GM-CSF 24% vs G-CSF 4%, p ¼ 0.0001). The highest incidence of ES was observed in breast cancer patients (42% of breast cancer patients; 70% of all ES cases). Comparison of the incidence of ES by the priming regimen used comprising either of the growth factors revealed no significant association (p ¼ 0.8224). This study demonstrates that the incidence of ES is higher using GM-CSF, particularly in patients with breast cancer. It suggests that it might be advantageous to administer only G-CSF in breast cancer patients undergoing AHSCT to reduce ES-related morbidity.
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The engraftment syndrome (ES) is a recently described phenomenon observed in some patients undergoing autologous hematopoietic stem cell transplant (AHSCT). ES has characteristic clinical findings of fever, skin rash, capillary leak, and pulmonary infiltrates observed during engraftment in patients after autologous BMT and/or AHSCT. 1 This phenomenon has also been termed 'autoaggression syndrome' by Moreb et al. 2 Recently, a uniform definition of ES has been proposed by Spitzer. 3 Clinically, the syndrome either resolves spontaneously or responds promptly to treatment with corticosteroids. Clinical variables predictive for increased risk of developing the syndrome include patients with breast cancer, 2 previous therapy with only one regimen, 2 higher number of mononuclear cells reinfused, 4 and administration of growth factors. 1, 5 . ES has been described with granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-colony-stimulating factor (G-CSF). Administration of either GM-CSF or G-CSF has been used at our institution after high-dose chemotherapy (HDC) and AHSCT. We performed a retrospective analysis, in a series of patients with solid tumors, hematological malignancies, and other diseases. We compared both growth factors and their role in the development of clinically significant ES 3 in patients requiring therapeutic intervention.
Patients and methods

Patients
We retrospectively reviewed the medical records of 174 consecutive patients at our institution treated with HDC followed by AHSCT for hematological malignancies, solid tumors, and other diseases from April 1996 through May 2000. All patients received either G-CSF or GM-CSF starting on day +1 and continuing until an absolute neutrophil count (ANC) of 41 Â 10 9 /l for 2 consecutive days was achieved. Growth factor selection was driven predominantly by the recommendations of the Pharmacy and Therapy Committee based upon acquisition costs to the institution. Patients on clinical trials received growth factors as per protocols. A total of 15 patients who were crossed over from GM-CSF to G-CSF after developing high-grade fever clinically considered secondary to GM-CSF, a known toxicity of this growth factor, 6 were excluded from the analysis. Patient characteristics are shown in Table 1 . The patient population included 95 females and 57 males, the male : female sex ratio was 1 : 1.67; age 23-72 years (median: 47 years). Malignancies included multiple myeloma (n ¼ 50), breast cancer (n ¼ 33), non-Hodgkin's lymphoma (n ¼ 30), Hodgkin's lymphoma (n ¼ 14), and other diseases (n ¼ 25).
Hematopoietic stem cell rescue was accomplished with autologous bone marrow (BM) (n ¼ 1) or peripheral blood stem cells (PBSC) (n ¼ 146) or both BM and PBSC (n ¼ 5). PBSC were collected by leukapheresis when WBC exceeded a minimum of 1 Â 10 9 /l using a Cobe Spectra 3000 cell separator (Gambro BCT, Lakewood, CO, USA). Three blood volumes (approximately 10 litres) were processed. Each leukapheresis product was analyzed for total mononuclear cell count and CD34+ cells. Cells were cryopreserved with 10% dimethylsulfoxide using a controlled rate freezer and were stored in the vapor phase of liquid nitrogen at À801C. Priming regimens included G-CSF alone (n ¼ 23), chemotherapy and G-CSF (n ¼ 103), chemotherapy and GM-CSF (n ¼ 24), G-CSF and GM-CSF (n ¼ 1), G-CSF and GM-CSF and chemotherapy (n ¼ 1). PBSC were processed and stored according to institutional guidelines. Following stem cell infusion, blood counts were performed on a daily basis. All patients received hematopoietic growth factor support starting on day +1 posttransplant: 87 patients (57.2%) received G-CSF while 65 (42.8%) received GM-CSF. Patients categorized as having ES required the following eligibility criteria. Major criteria: fever over 38.31C with no identifiable infectious etiology, erythrodermatous rash involving more than 25% of body surface area and not attributable to a medication, and pulmonary edema manifested by diffuse pulmonary infiltrates consistent with this diagnosis, and hypoxia. Minor criteria: hepatic dysfunction with either total bilirubin X2 mg/dl or transaminase levels X2 times normal, renal insufficiency (serum creatinine of X2 times baseline), weight gain X2.5% of baseline body weight, transient encephalopathy unexplainable by other causes. A diagnosis of ES was established by the presence of all three major criteria or two major and one or more minor criteria. 3 ES should occur within 96 h of engraftment (neutrophil count of X500/ml for 2 consecutive days).
As part of the fever evaluation, all patients had blood and urine cultures, and chest radiographs performed with appropriate additional evaluations as clinically indicated (e.g. chest CT, pulmonary consultation). Supportive care included broad-spectrum antibiotic coverage against bacteria, fungi and viruses as per institutional guidelines (with some change in the guidelines over the 4-year period). This usually included the prophylactic use of a third-or fourthgeneration cephalosporin (i.e. cefepime) administered intravenously when the ANC dropped below 0.5 Â 10 9 /l. At the onset of the first neutropenic fever over 38.31C, vancomycin was added to the antibiotic coverage and was discontinued after 72 h if all cultures were negative for vancomycin-susceptible organisms. Empirical intravenous amphotercin-B was added for nonresponding fever over 3 days with negative cultures. These regimens were continued until patients reached ANC41 Â 10 9 /l for 2 days and became afebrile. In addition, persistent neutropenic febrile episodes were investigated with chest CT scans and/or bronchoscopy with bronchoalveolar lavage.
Skin biopsies were performed in 99 patients, which revealed the presence of necrotic keratinocytes and satellite cell necrosis, vacuolar interface dermatitis, and sparse superficial perivascular lymphocytic infiltration, changes that were inseparable from acute GVHD.
After exclusion of potential infectious etiologies, usually after a minimum of 48 h, steroids were administered in the form of methylprednisolone 1-2 mg/kg/day with rapid tapering over the ensuing 2 weeks (14 days in total).
Statistical analysis
Patients meeting the definition of ES were compared with the remainder of the group who did not develop the syndrome. Clinical variables affecting the incidence of the syndrome were analyzed and included: gender, CD34+ cells/kg infused, type of growth factor, the priming regimen, and disease type. The Fisher's exact test statistic was used to compare the development of ES and the type of growth factor used. The Wilcoxon signed rank test was used to compare the number of CD34+ cells/kg infused and the risk of developing ES. A multivariate logistic 
Results
Patients with clinically significant ES (those patients with persistent/worsening ES-related symptoms/signs, usually high fever and rash) were included in this analysis. In all, 20 patients (13%) (18 females and two males : female gender predilection, p ¼ 0.004) met the criteria for ES. Of the 20 patients, 14 were females undergoing HDC for breast cancer (Table 1) . Whereas breast cancer accounted for 22% of all transplants in this series, 70% of ES patients had breast cancer. The incidence of ES varied with the underlying disease: it was highest in adjuvant breast cancer patients (12/23; 52%) compared to stage IV breast cancer patients (2/10; 20%). The use of GM-CSF in adjuvant breast cancer patients was significantly associated with the development of ES (Table 2) . ES was seen more frequently in patients who received GM-CSF post-transplant (GM-CSF 24% vs G-CSF 4%, p ¼ 0.0001).
The relationship between the CD34+ cell dose and the likelihood of developing ES was statistically significant in univariate analysis. The median number of CD34+ cells infused was 6.9 Â 10 6 /kg for patients who developed ES vs 5.1 Â 10 6 /kg (p ¼ 0.0465). In addition, the median number of CD34+ cells infused was 7.5 Â 10 6 /kg for patients treated with GM-CSF and developed ES vs 5.9 Â 10 6 /kg for patients treated with G-CSF who developed ES. In a multivariate logistic regression analysis used to compare simultaneously the effect of growth factor and CD34+ cell dose, controlling for a specific growth factor, the CD34+ dose was not significant (p ¼ 0. ¼ 14) , germ cell tumor (n ¼ 5), multiple sclerosis (n ¼ 5), ALL (n ¼ 2), amyloidosis (n ¼ 2), and sarcomas (n ¼ 2).
Discussion
The true incidence of ES has not been described in a large population of patients. However, the reported incidence of the syndrome is understandably variable given the breadth of definitions and ranges from 6.9% as studied by Edenfield et al 7 to nearly 60% as reported by Lee et al 1 following autologous transplantation. In our study we report a 13% incidence of clinically relevant ES, as defined by Spitzer, 3 those requiring therapeutic intervention. ES has been recently described in 10 out of 110 (9%) patients after allogeneic HSCT characterizing this entity as a clinically distinct syndrome from acute GVHD. 8 Autologous GVHD described by Kennedy et al 9 is another distinct clinical entity affecting breast cancer patients based upon induced GVHD by cyclosporine use then withdrawal and involves the skin only with changes identical to allogeneic GVHD. Colby et al 10 observed ES in the majority of recipients of HLA-matched donor BMT for hematologic malignancies undergoing nonmyeloablative preparative regimens consisting of cyclophosphamide, peritransplant antithymocyte globulin, pretransplant thymic irradiation, and post-transplant cyclosporine. The observation that histopathologic changes of acute GVHD are often seen in skin biopsies of patients with autologous ES suggests that there is an important clinical and pathophysiologic interface of ES and autologous GVHD. 2 The distinctive clinical feature of ES is its occurrence at the time of neutrophil recovery, the presence of capillary leak, and renal involvement -features not seen in GVHD.
The contributory role of growth factors in the development of ES has been reported by several investigators: Lee et al 1 demonstrated a significant association of G-CSF use with the development of ES (po0.01). The use of growth factors to mobilize stem cells has also previously been shown to be a risk factor for ES. 7 Other series have noted lesser 5 or no association 2,7 with cytokine administration. Our study went one step further and showed that the incidence of ES was higher with the use GM-CSF compared to G-CSF, especially in breast cancer patients. As shown in Table 1 , patients developing ES received significantly more CD34+ progenitor cells than those patients who did not develop the syndrome (6.9 Â 10 6 /kg vs 5.1 Â 10 6 /kg, p ¼ 0.0465). However, in a multivariate regression analysis, the growth factor (GM-CSF) was the important variable for predicting ES, not the CD34+ cell dose. Other investigators found no correlation of the development of ES with the number of CD34+ cells infused. 11, 12 The results of our study do not support the Comparison of the number of patients (in the adjuvant breast cancer group) with (ES+) and (ESÀ) according to the growth factor used. 5 who reported an association of ES with early and steep neutrophil recovery pointing to a role for the neutrophils in the pathogenesis of the syndrome. In contrast to neutrophil recovery, platelet recovery was not significantly affected in patients who developed ES. In addition, Sutkowi et al 11 showed that ES does not affect WBC or platelet engraftment.
Although the pathogenesis of ES is not known, it has been hypothesized that mechanisms that normally safeguard the self-tolerance properties of the immune system are suppressed by HDC. 2 Moreb et al 2 showed that two or more previous chemotherapy regimens given to breast cancer patients undergoing HDC and AHSCT were associated with a less likelihood of developing the 'autoaggression syndrome'. This group postulated that patients with breast cancer are at higher risk of developing ES compared to lymphoma patients, and that such a difference could be attributed to an immune system that is less suppressed in breast cancer patients. 2 In addition, this same group recently described that breast cancer patients with ES had a poorer long-term survival compared to breast cancer patients without ES. 12 By showing that patients with breast cancer who developed ES have higher mortality rates, their hypothesis is that ES might indicate widely micrometastatic disease at the time of transplantation, and, therefore, ES may be a manifestation of the immune response against an existing residual tumor.
With the routine use of growth factor support posttransplant, transplant physicians are more likely to be faced with ES especially in breast cancer patients. During the periengraftment period, the rapid neutrophil recovery, under the effects of exogenous G-CSF and GM-CSF and endogenous inflammatory cytokines present at engraftment, [13] [14] [15] [16] could result in the clinical syndrome. In addition, GM-CSF has the capacity to stimulate dendritic cell activation and proliferation, and can cause capillary leak syndrome. 17 We conclude that ES is a relatively benign phenomenon that can be corrected with a short course of systemic corticosteroids. However, to reduce the incidence ES, and the subsequent morbidity associated with the syndrome and its treatment, it would be advantageous to avoid using GM-CSF as a post-transplant growth factor support in breast cancer patients undergoing HDC and AHSCT.
